Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. (VTYX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
vtyx · stock forecast · 13 analysts (3M) · FMP · updated Mar 12, 2026
Analyst Rating & Consensus
Based on 13 Wall Street analysts in the past 3 months
Hold
13 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$14.00
Consensus
$14.00
+0.0% upside
Low
$14.00
Median: $14 · Last Close: $14.00
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
BullAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $14.01 | ↑ 0.05% |
1-day model range: $14–$14.01. Peak: $14.01 (+0.05%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BULLISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · VTYX · Jun 8, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-01-08 | Wells Fargo | Downgrade ↓ | Overweight→Equal Weight |
| 2026-01-08 | HC Wainwright & Co. | Downgrade ↓ | Buy→Neutral |
| 2026-01-08 | Oppenheimer | Downgrade ↓ | Outperform→Perform |
| 2026-01-08 | Canaccord Genuity | Downgrade ↓ | Buy→Hold |
| 2026-01-08 | UBS | Downgrade ↓ | Buy→Neutral |
| 2026-01-08 | LifeSci Capital | Downgrade ↓ | Outperform→Market Perform |
| 2025-11-07 | Wells Fargo | Maintains | Overweight→Overweight |
| 2025-11-07 | Canaccord Genuity | Maintains | Buy→Buy |
| 2025-11-05 | HC Wainwright & Co. | Upgrade ↑ | Neutral→Buy |
| 2025-10-27 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Ventyx Biosciences, Inc. (VTYX) stock. Of the recent 60 rating actions, 3 were upgrades and 10 were downgrades. 13 analysts currently cover VTYX.
Analyst Recommendation Trends
VTYX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 0 to 0 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
↓ 100.0% YoY
Revenue Next Year
$13M
EPS This Year
$-1.47
EPS Next Year
$-1.77
↑ 20.3% YoY
EPS ForecastReported vs Estimated
Analysts forecast VTYX EPS of $-1.47 for the current fiscal year, based on estimates from 5 analysts. The VTYX revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The VTYX stock forecast is supported by two independent data sources: analyst consensus ratings from 13 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus VTYX price target is $14.00 (+0.0% upside), with an analyst consensus of Hold.
The VTYX short-term stock prediction for tomorrow is $14.01 (+0.05%).
Ventyx Biosciences, Inc. trades on NASDAQ under the ticker VTYX. The VTYX stock outlook for 2027 is broadly mixed, supported by a Hold consensus among 31% of covering analysts.
Frequently asked questions
VTYX forecast · 8 questionsAccording to 13 Wall Street analysts, the average 12-month VTYX price target is $14.00, with a high forecast of $14.00 and a low of $14.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $14.00.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.